Zylox-Tonbridge Medical Technology Co., Ltd.
歸創通橋醫療科技股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2190)

VOLUNTARY ANNOUNCEMENT
UPDATE ON SHARE REPURCHASE

This announcement is made by Zylox-Tonbridge Medical Technology Co., Ltd. (the "**Company**") on a voluntary basis.

Reference is made to the announcement of the Company dated 25 April 2025 (the "**Announcement**") in relation to the Company's H share repurchase plan (the "**H Share Repurchase Plan**"). Unless otherwise defined herein, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

To enhance the Company's market capitalisation management and create long-term value for the Shareholders, approximately HK$97 million (excluding transaction costs) has been used for on-market H Share repurchase during the three months up to the date of this announcement. Pursuant to the H Share Repurchase Plan, the maximum amount for the Company to repurchase its H Shares is HK$650 million. As at the date of this announcement, the remaining fund available for H Share repurchase under the H Share Repurchase Plan is approximately HK$300 million. The Company will continue to conduct on-market repurchases of its H shares from time to time under the general mandate granted by the Shareholders to the Board at the general meetings of the Company held on 13 May 2026 and, where applicable, any future general mandate to repurchase H Shares as approved by the Shareholders at the general meeting of the Company from time to time.

The Company believes that the continuous share repurchases demonstrate the Company's confidence in its business development prospects, core competitiveness and long-term operational resilience. The Board is of the view that the Company's current financial resources are sufficient to support the implementation of the share repurchase while maintaining a solid financial position.

Shareholders and potential investors should note that the implementation of the on-market share repurchase by the Company will be subject to market conditions and will be at the absolute discretion of the Board and/or its authorised person(s). There is no assurance of the timing, quantity or price of any repurchases or whether the Company will make any repurchases at all. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Zylox-Tonbridge Medical Technology Co., Ltd.
Dr. Jonathon Zhong Zhao
Chairman and Executive Director

Hong Kong, 15 June 2026

As at the date of this announcement, the Board comprises Dr. Jonathon Zhong Zhao, Mr. Yang Xie and Dr. Zheng Li as executive Directors, Dr. Steven Dasong Wang and Mr. Dongfang Li as non-executive Directors, and Dr. Jian Ji, Ms. Yun Qiu and Dr. Xiang Qian as independent non-executive Directors.